Skip to main content

RAD April 2023 Conference Abstracts and Posters

All accepted abstracts have been published in The British Journal of Dermatology, Volume 188, Issue Supplement 3, June 2023. You may access the publication at:

#431 - Assessment of racial and ethnic differences of atopic dermatitis severity and treatment patterns in a diverse outpatient cohort in the United States

Eric Sanfilippo, Sneha Iyer, Nisha Patel, Jonathan I. Silverberg

#432 - Comparative treatment persistence of different advanced-therapies in patients with atopic dermatitis

Eric Sanfilippo, Sneha Iyer, Jonathan I. Silverberg

#433 - Outcome measures demographics and characteristics in predicting HE severity in AD patients

Archana Samynathan, Jonathan I. Silverberg

#434 - Efficacy and safety of crisaborole ointment, 2%, in Chinese and Japanese pediatric patients aged 2-17 years with mild-to-moderate atopic dermatitis

Jianzhong Zhang, Lin Ma, Shan Wang, Ping Li, Yunsheng Liang, Qiufang Qian, Amy Cha, Juliana M. Canosa, Yangmei Zhou, Yayuan Chen, Yinghui Li

#435 - Burden of disease and unmet needs in the diagnosis and management of atopic dermatitis in the Middle East

Omar Mahmoud, Enas Attia, Gil Yosipovitch

#436 - Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: results from a phase 3 trial (OLYMPIA 2)

Sonja Ständer, Gil Yosipovitch, Franz J. Legat, Adam Reich, Carle Paul, Dagmar Simon, Luigi Naldi, Jonathan I. Silverberg, Rola Gharib, Alan Fleischer, Vivian T. Laquer, Faiz Ahmad, Zarif Jabbar-Lopez, Christophe Piketty, Shawn G. Kwatra

#437 - Treatment-emergent adverse events in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis treated with dupilumab in an open-label extension clinical trial

Amy S. Paller, Elaine C. Siegfried, Robert Sidbury, Benjamin Lockshin, Michael Cork, Andreas Pinter, Jing Xiao, Faisal A. Khokhar, Ashish Bansal, Randy Prescilla

#438 - Potentially greater efficacy with CBP-201 for adults with severe versus moderate atopic dermatitis at baseline: subgroup analyses from the WW001 phase 2 randomized trial

Lisa A. Beck, Jonathan I. Silverberg, Jang Yun, Zheng Wei, Raúl Collazo, Chin Lee

#439 - Patients with mild to moderate atopic dermatitis: a first-in-human, open-label, dose-escalating, non-randomized clinical trials with AMTX-100

Yashar Salek, Masoumeh Dejman, Arezou Bayat, Hana Mekonnen, Vernon A. Alvarez, Matthew A. Gonda

#440 - Prevalence and burden of rhinoconjunctivitis in atopic dermatitis patients: A cross-sectional study

Isaac Betaharon, Jonathan I. Silverberg

Page 6 of 6
Results 51 - 60 of 60